The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.